Neurosurgical Use of Interstitial Laser Therapy (ILT) (ILT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00207350|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : February 23, 2017
The researchers' specific aims are to test the following hypotheses:
Hypothesis 1: A tumor can be completely ablated by ILT with MRI-guidance.
Hypothesis 2: The MRI-based 3D temperature map of tissue during ILT is predictive of destruction.
Hypothesis 3: The 3D "thermal dose" map that is based on the tissue's temperature over time is more predictive of tissue destruction than the temperature map.
|Condition or disease||Intervention/treatment||Phase|
|Brain Tumor||Device: Interstitial Laser Therapy||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neurosurgical Use of Interstitial Laser Therapy (ILT)|
|Study Start Date :||January 2002|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||December 2006|
Neurosurgical use of Interstitial Laser therapy
Device: Interstitial Laser Therapy
Other Name: ILT
- Ablation of lesion [ Time Frame: During procedure ]
- Patients undergoing ILT will be assessed pre- and post-operatively based on a neurological exam by a physician and patient self-assessment using the Glioma Outcomes Questionnaire [ Time Frame: 3 Months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207350
|United States, Massachusetts|
|Brigham & Women's Hospital|
|Boston, Massachusetts, United States, 02155|
|Principal Investigator:||Golby Alexandra, MD||Brigham and Women's Hospital|